Molly B. Schmid,
PhD
Professor, Entrepreneur-in-Residence, Director of ResearchAreas of Expertise:
- Antimicrobial Drug Discovery
- Pharmaceutical Development
Molly Schmid is a Professor and Entrepreneur-in-Residence at Keck Graduate Institute of Applied Life Sciences. She teaches courses on entrepreneurship and the science and business aspects of drug discovery and development. Her research focus is in the areas of chemical genetics and antimicrobial drug discovery. While an Assistant Professor of Molecular Biology at Princeton University her research group discovered Topoisomerase IV in Salmonella typhimurium, as well as a genetic strategy for identifying new antimicrobial targets. She has seven issued U.S. patents, and several others pending.
Prior to coming to Keck Graduate Institute, she spent ten years in the biotechnology industry, most recently as Senior Vice President of Preclinical Programs at Affinium Pharmaceuticals in Toronto, Ontario. She is a Fellow of the American Academy of Microbiology, a Searle/Chicago Community Trust Scholar and a Damon Runyon-Walter Winchell Fellow. Dr. Schmid earned her PhD in biology from the University of Utah and her undergraduate degree in biology from SUNY Albany.
Last updated 12.14.2006
|
| Schmid, M.B. Crystallizing new approaches for antimicrobial drug discovery. Biochemical Pharmacology 7, 1048-1056 (2006).
Schmid, M.B. Do targets limit antibiotic discovery? Nature Biotechnology 24, 419-420 (2006).
Martin PK, Bao Y, Boyer E, Winterberg KM, McDowell L, Schmid MB, Buysse JM. (2002) Novel locus required for expression of high-level macrolide-lincosamide-streptogramin B resistance in Staphylococcus aureus. J Bacteriol. 184:5810-3.
Schmid M.B. (2002) Structural proteomics: the potential of high-throughput structure determination. Trends in Microbiol. 10: S27-31.
Schmid MB, Kaplan N. (2004) Reduced triclosan susceptibility in methicillin resistant Staphylococcus epidermidis. Antimicrob. Agents Chemother. 48: 1397-99.
Schmid MB. (2004) Structural Genomics: The Impact on Antimicrobial Discovery. Nature Microbiol. Reviews 2:739-746.
Benton B.M, Zhang JP, Bond S, Pope C, Christian T, Lee L, Winterberg KM, Schmid MB, Buysse JM. (2004) Identification of new genes required for in vivo growth or survival of Staphylococcus aureus. J. Bacteriol. 186: 8478-89.
Kimber MS, Martin F, Lu Y, Houston, S, Vedadi, M, Dharamsi, A, Fiebig KM, Schmid M, Rock CO. (2004) The Structure of (3R)-Hydroxyacyl–Acyl Carrier Protein Dehydratase (FabZ) from Pseudomonas aeruginosa. J. Biol. Chem. 279: 52593-52602.
Schmid, MB. (2006) Crystallizing new approaches for antibiotic drug discovery. Biochem. Pharmacol. Biochem Pharmacol. 71: 1048-56.
Schmid, MB. (2006) Do targets limit antibiotic discovery? Nature Biotech. 24: 419-20. |
12.14.2006
|
US 5,962,249
Sized-based marker identification technology. Benton, B.; Bostian, K.; Schmid, M.B.; Sun, D.; Buysse J.M. (1999).
US 6,037,123
Methods of screening for compounds active on Staphylococcus aureus. Benton, B.; Lee, V.; Malouin, F.; Martin, P.; Schmid, M.; Sun, D-X. (2000)
US 6,187,541
Methods of screening for compounds active on staphylococcus aureus target genes. Benton, B.; Lee, V.; Malouin, F.; Martin, P.; Schmid, M.; Sun, D-X. (2001)
US 6,228,588
Methods of screening for compounds active on Staphylococcus aureus target genes. Benton, B.; Lee, V.; Malouin, F.; Martin, P.; Schmid, M.; Sun, D-X. (2001)
US 6,514,746
Staphylococcus aureus histidine protein kinase essential genes. Benton, B.; Malouin, F.; Martin, P.; Schmid, M.; Sun, D-X. (2003)
US 6,630,303
Methods of screening for compounds active on Staphylococcus aureus target genes. Benton, B.; Lee, V.; Malouin, F.; Martin, P.; Schmid, M.; Sun, D-X. (2003)
US 6,638,718
Methods of screening for compounds active on Staphylococcus aureus target genes. Benton, B.; Lee, V.; Malouin, F.; Martin, P.; Schmid, M.; Sun, D-X. (2003)
Several additional patent applications are pending as US and PCT applications. |
|
|
 |
 Contact InformationMolly Schmid
909/607-8565
Molly_Schmid@kgi.edu
|
